REG - Cambridge Cognition - £2.2m neurodegenerative disease trial contract

Cambridge Cognition HoldingsAnnouncement

01/09/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220901:nRSA8231Xa&default-theme=true

RNS Number : 8231X  Cambridge Cognition Holdings PLC  01 September 2022

 

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition" or the "Company")

 

Cambridge Cognition wins £2.2 million neurodegenerative disease trial

 

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce that it has
won a £2.2 million contract providing cognitive assessments and electronic
diaries for a neurodegenerative disease trial.  Revenue from the contract is
expected over the next two financial years.  This is a follow-on sale from a
£2.1 million contract announced by the Company on 2 February 2022 with the
same customer.

 

One person develops dementia every three minutes(1), making neurodegenerative
diseases a key target for drug development. To develop effective treatments,
sensitive and specific cognitive assessments are essential as cognitive
dysfunction is a hallmark of neurodegenerative diseases.  With unrivalled use
in over 2,500 peer-reviewed publications, and a reputation for excellent
customer service, Cambridge Cognition has been selected as the cognitive
assessment partner for this series of treatment trials.

 

In delivering the contract, Cambridge Cognition will provide the technology
for a hybrid trial, combining in-clinic with at home cognitive assessments.
This will enable the Company to offer more detailed insights into the
development of disease over time and the efficacy of new pharmaceutical
compounds.

 

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:

"We are pleased to have further strengthened our relationship with this
pharmaceutical customer that is committed to tackling neurodegenerative
disease.  Cambridge Cognition has a strong history of delivering cognitive
assessments in the field, traditionally in clinics and now also at home.  The
quick succession of large contracts from this customer is a testament to both
the efficacy of our products and quality of our service."

 

References

1.
https://www.alzheimers.org.uk/about-us/news-and-media/facts-media
(https://www.alzheimers.org.uk/about-us/news-and-media/facts-media)

 

For further information, contact:

 

 Cambridge Cognition Holdings Plc                      Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer
 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)  Tel: 020 7886 2968

 Freddy Crossley / Emma Earl                           (Corporate Finance)

 Rupert Dearden                                        (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)                Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)                Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTBUGDICSXDGDB